These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. [Effects of ST1571 on the development of dendritic cells derived from bone marrow mononuclear cells in patients with chronic myeloid leukemia]. Zheng SE; Jin J; Tong XM; Qian WB; Xue YQ Zhonghua Zhong Liu Za Zhi; 2006 Dec; 28(12):920-3. PubMed ID: 17533744 [TBL] [Abstract][Full Text] [Related]
6. In vivo effects of imatinib mesylate on human haematopoietic progenitor cells. Agis H; Jaeger E; Doninger B; Sillaber C; Marosi C; Drach J; Schwarzinger I; Valent P; Oehler L Eur J Clin Invest; 2006 Jun; 36(6):402-8. PubMed ID: 16684124 [TBL] [Abstract][Full Text] [Related]
7. Normal intrinsic Th1/Th2 balance in patients with chronic phase chronic myeloid leukemia not treated with interferon-alpha or imatinib. Kiani A; Habermann I; Schäke K; Neubauer A; Rogge L; Ehninger G Haematologica; 2003 Jul; 88(7):754-61. PubMed ID: 12857553 [TBL] [Abstract][Full Text] [Related]
8. Increased IFN-gamma synthesis by T cells from patients on imatinib therapy for chronic myeloid leukemia. Aswald JM; Lipton JH; Aswald S; Messner HA Cytokines Cell Mol Ther; 2002; 7(4):143-9. PubMed ID: 14660054 [TBL] [Abstract][Full Text] [Related]
9. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. Hughes TP; Kaeda J; Branford S; Rudzki Z; Hochhaus A; Hensley ML; Gathmann I; Bolton AE; van Hoomissen IC; Goldman JM; Radich JP; N Engl J Med; 2003 Oct; 349(15):1423-32. PubMed ID: 14534335 [TBL] [Abstract][Full Text] [Related]
10. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase]. Zhang GC; Zheng D; Li QH; Li XH; Cai CC; Luo SK; Li J; Peng AH; Tong XZ; Tan EX; Hong WD Ai Zheng; 2004 Dec; 23(12):1696-9. PubMed ID: 15601563 [TBL] [Abstract][Full Text] [Related]
11. [Monitoring bcr/abl mRNA levels in imatinib mesylate treated chronic myeloid leukemia patients by real-time quantitative RT-PCR]. Qin YZ; Ruan GR; Liu YR; Li JL; Fu JY; Wang H; Chang Y; Jiang B; Jiang Q; Jiang H; Qiu JY; Chen SS; Lu DP Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):1-5. PubMed ID: 15946498 [TBL] [Abstract][Full Text] [Related]
12. [Psoriasis vulgaris exacerbated by imatinib therapy in chronic myelogenous leukemia]. Shimizu K; Kuroda H; Kida M; Watanabe H; Shirao S; Akiyama T; Fujimi A; Tanaka I; Sato T; Matsunaga T; Niitsu Y Rinsho Ketsueki; 2005 Oct; 46(10):1152-5. PubMed ID: 16440780 [TBL] [Abstract][Full Text] [Related]
13. Imatinib mesylate does not impair the immunogenicity of human myeloid blood dendritic cells. Wehner R; Wendisch M; Schäkel K; Bornhäuser M; Platzbecker U; Mohr B; Temme A; Bachmann M; Rieber EP; Schmitz M Leukemia; 2006 Sep; 20(9):1629-32. PubMed ID: 16838025 [No Abstract] [Full Text] [Related]
14. Acute myeloid leukemia developing during imatinib mesylate therapy for chronic myeloid leukemia in the absence of new cytogenetic abnormalities. Pawarode A; Sait SN; Nganga A; Coignet LJ; Barcos M; Baer MR Leuk Res; 2007 Nov; 31(11):1589-92. PubMed ID: 17391756 [TBL] [Abstract][Full Text] [Related]
15. Imatinib mesylate minimally affects bcr-abl+ and normal monocyte-derived dendritic cells but strongly inhibits T cell expansion despite reciprocal dendritic cell-T cell activation. Boissel N; Rousselot P; Raffoux E; Cayuela JM; Soulier J; Mooney N; Charron D; Dombret H; Toubert A; Rea D J Leukoc Biol; 2006 Apr; 79(4):747-56. PubMed ID: 16461746 [TBL] [Abstract][Full Text] [Related]